More information: Matteo Iannacone et al, Targeting HBV with RNA interference: Paths to cure, Science Translational Medicine (2025). DOI: 10.1126/scitranslmed.adv3678 ...

Six RNA interference-based drugs have already been approved by the United States (U.S.) Alnylam Pharmaceuticals has developed the Food and Drug Administration (FDA) and five of these.

As shown in STAT’s Obesity Drug Tracker, Regeneron and others are using RNA interference to target genetics, rather than hormones like GLP-1.